198 related articles for article (PubMed ID: 14533120)
1. Clinical predictors of response to Acetyl Cholinesterase Inhibitors: experience from routine clinical use in Newcastle.
Pakrasi S; Mukaetova-Ladinska EB; McKeith IG; O'Brien JT
Int J Geriatr Psychiatry; 2003 Oct; 18(10):879-86. PubMed ID: 14533120
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies.
Thomas AJ; Burn DJ; Rowan EN; Littlewood E; Newby J; Cousins D; Pakrasi S; Richardson J; Sanders J; McKeith IG
Int J Geriatr Psychiatry; 2005 Oct; 20(10):938-44. PubMed ID: 16163744
[TBL] [Abstract][Full Text] [Related]
3. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia.
Minett TS; Thomas A; Wilkinson LM; Daniel SL; Sanders J; Richardson J; Littlewood E; Myint P; Newby J; McKeith IG
Int J Geriatr Psychiatry; 2003 Nov; 18(11):988-93. PubMed ID: 14618549
[TBL] [Abstract][Full Text] [Related]
4. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia.
Aarsland D; Hutchinson M; Larsen JP
Int J Geriatr Psychiatry; 2003 Oct; 18(10):937-41. PubMed ID: 14533126
[TBL] [Abstract][Full Text] [Related]
5. Cerebral white matter changes and rate of progression of dementia during cholinesterase inhibitor treatment: a retrospective cohort study.
Devine ME; Fonseca JA; Walker RW; Sikdar T; Stevens T; Walker Z
Int J Geriatr Psychiatry; 2007 Nov; 22(11):1120-6. PubMed ID: 17457951
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of acetyl-cholinesterase-inhibitor (ACHEI) treatment in Alzheimer's disease: a 21-month follow-up "real world" study.
Calabria M; Geroldi C; Lussignoli G; Sabbatini F; Zanetti O
Arch Gerontol Geriatr; 2009; 49(1):e6-11. PubMed ID: 18768226
[TBL] [Abstract][Full Text] [Related]
7. EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up.
Bonanni L; Thomas A; Tiraboschi P; Perfetti B; Varanese S; Onofrj M
Brain; 2008 Mar; 131(Pt 3):690-705. PubMed ID: 18202105
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of acetylcholinesterase inhibitors: diagnosis and severity as predictors of response in routine practice.
Van Der Putt R; Dineen C; Janes D; Series H; McShane R
Int J Geriatr Psychiatry; 2006 Aug; 21(8):755-60. PubMed ID: 16906631
[TBL] [Abstract][Full Text] [Related]
9. Pentagon drawing and neuropsychological performance in Dementia with Lewy Bodies, Alzheimer's disease, Parkinson's disease and Parkinson's disease with dementia.
Cormack F; Aarsland D; Ballard C; Tovée MJ
Int J Geriatr Psychiatry; 2004 Apr; 19(4):371-7. PubMed ID: 15065231
[TBL] [Abstract][Full Text] [Related]
10. Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies.
Aarsland D; Mosimann UP; McKeith IG
J Geriatr Psychiatry Neurol; 2004 Sep; 17(3):164-71. PubMed ID: 15312280
[TBL] [Abstract][Full Text] [Related]
11. Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease.
Burn DJ; McKeith IG
Mov Disord; 2003 Sep; 18 Suppl 6():S72-9. PubMed ID: 14502659
[TBL] [Abstract][Full Text] [Related]
12. Visual hallucinations and altered visual information processing in Parkinson disease and dementia with Lewy bodies.
Kurita A; Murakami M; Takagi S; Matsushima M; Suzuki M
Mov Disord; 2010 Jan; 25(2):167-71. PubMed ID: 20063433
[TBL] [Abstract][Full Text] [Related]
13. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias.
Aarsland D; Perry R; Larsen JP; McKeith IG; O'Brien JT; Perry EK; Burn D; Ballard CG
J Clin Psychiatry; 2005 May; 66(5):633-7. PubMed ID: 15889951
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of degenerative dementia disorders--who should be treated?].
Hasselbalch SG; Kampmann JP
Ugeskr Laeger; 2009 Mar; 171(10):802-5. PubMed ID: 19265606
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal study of cerebral blood flow SPECT in Parkinson's disease with dementia, and dementia with Lewy bodies.
Firbank MJ; Burn DJ; McKeith IG; O'Brien JT
Int J Geriatr Psychiatry; 2005 Aug; 20(8):776-82. PubMed ID: 16035122
[TBL] [Abstract][Full Text] [Related]
16. Clinical phenotype of Parkinson disease dementia.
Galvin JE; Pollack J; Morris JC
Neurology; 2006 Nov; 67(9):1605-11. PubMed ID: 17101891
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study.
Edwards K; Royall D; Hershey L; Lichter D; Hake A; Farlow M; Pasquier F; Johnson S
Dement Geriatr Cogn Disord; 2007; 23(6):401-5. PubMed ID: 17409748
[TBL] [Abstract][Full Text] [Related]
18. [Characterisation and prevalence of the psychological and behavioural symptoms in patients with dementia].
López-Pousa S; Vilalta-Franch J; Garre-Olmo J; Pons S; Cucurella MG
Rev Neurol; 2007 Dec 1-15; 45(11):683-8. PubMed ID: 18050101
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of Parkinson's disease dementia: association with aging and visual hallucination.
Kitayama M; Wada-Isoe K; Nakaso K; Irizawa Y; Nakashima K
Acta Neurol Scand; 2007 Sep; 116(3):190-5. PubMed ID: 17714333
[TBL] [Abstract][Full Text] [Related]
20. A qualitative analysis of the mini mental state examination on Alzheimer's disease patients treated with cholinesterase inhibitors.
Lucchi E; Minicuci N; Magnifico F; Mondini S; Calza A; Avanzi S; Villani D; Bellelli G; Trabucchi M
Arch Gerontol Geriatr Suppl; 2004; (9):253-63. PubMed ID: 15207422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
